238 related articles for article (PubMed ID: 31187490)
21. A novel DNA-binding motif in prostate tumor overexpressed-1 (PTOV1) required for the expression of ALDH1A1 and CCNG2 in cancer cells.
Maggio V; Cánovas V; Félix AJ; Gómez V; de Torres I; Semidey ME; Morote J; Noé V; Ciudad CJ; Paciucci R
Cancer Lett; 2019 Jun; 452():158-167. PubMed ID: 30922918
[TBL] [Abstract][Full Text] [Related]
22. All-trans retinoic acid downregulates ALDH1-mediated stemness and inhibits tumour formation in ovarian cancer cells.
Young MJ; Wu YH; Chiu WT; Weng TY; Huang YF; Chou CY
Carcinogenesis; 2015 Apr; 36(4):498-507. PubMed ID: 25742746
[TBL] [Abstract][Full Text] [Related]
23. ALDH1A1+ ovarian cancer stem cells co-expressing surface markers CD24, EPHA1 and CD9 form tumours in vivo.
Nagare RP; Sneha S; Krishnapriya S; Ramachandran B; Murhekar K; Vasudevan S; Shabna A; Ganesan TS
Exp Cell Res; 2020 Jul; 392(1):112009. PubMed ID: 32305326
[TBL] [Abstract][Full Text] [Related]
24. Aldehyde dehydrogenase activity plays a Key role in the aggressive phenotype of neuroblastoma.
Flahaut M; Jauquier N; Chevalier N; Nardou K; Balmas Bourloud K; Joseph JM; Barras D; Widmann C; Gross N; Renella R; Mühlethaler-Mottet A
BMC Cancer; 2016 Oct; 16(1):781. PubMed ID: 27724856
[TBL] [Abstract][Full Text] [Related]
25. ALDH1A1 drives prostate cancer metastases and radioresistance by interplay with AR- and RAR-dependent transcription.
Gorodetska I; Offermann A; Püschel J; Lukiyanchuk V; Gaete D; Kurzyukova A; Freytag V; Haider MT; Fjeldbo CS; Di Gaetano S; Schwarz FM; Patil S; Borkowetz A; Erb HHH; Baniahmad A; Mircetic J; Lyng H; Löck S; Linge A; Lange T; Knopf F; Wielockx B; Krause M; Perner S; Dubrovska A
Theranostics; 2024; 14(2):714-737. PubMed ID: 38169509
[No Abstract] [Full Text] [Related]
26. EHMT1 promotes tumor progression and maintains stemness by regulating ALDH1A1 expression in alveolar rhabdomyosarcoma.
Nachiyappan A; Soon JLJ; Lim HJ; Lee VK; Taneja R
J Pathol; 2022 Mar; 256(3):349-362. PubMed ID: 34897678
[TBL] [Abstract][Full Text] [Related]
27. TAZ induces lung cancer stem cell properties and tumorigenesis by up-regulating ALDH1A1.
Yu J; Alharbi A; Shan H; Hao Y; Snetsinger B; Rauh MJ; Yang X
Oncotarget; 2017 Jun; 8(24):38426-38443. PubMed ID: 28415606
[TBL] [Abstract][Full Text] [Related]
28. Discovery of coumarin-based selective aldehyde dehydrogenase 1A1 inhibitors with glucose metabolism improving activity.
Liang D; Fan Y; Yang Z; Zhang Z; Liu M; Liu L; Jiang C
Eur J Med Chem; 2020 Feb; 187():111923. PubMed ID: 31816557
[TBL] [Abstract][Full Text] [Related]
29. Patterns of stemness-associated markers in the development of castration-resistant prostate cancer.
Federer-Gsponer JR; Müller DC; Zellweger T; Eggimann M; Marston K; Ruiz C; Seifert HH; Rentsch CA; Bubendorf L; Le Magnen C
Prostate; 2020 Sep; 80(13):1108-1117. PubMed ID: 32628318
[TBL] [Abstract][Full Text] [Related]
30. Impact of the thyroid hormone T3 and its nuclear receptor TRα1 on colon cancer stem cell phenotypes and response to chemotherapies.
Giolito MV; Bodoirat S; La Rosa T; Reslinger M; Guardia GDA; Mourtada J; Claret L; Joung A; Galante PAF; Penalva LOF; Plateroti M
Cell Death Dis; 2024 May; 15(5):306. PubMed ID: 38693105
[TBL] [Abstract][Full Text] [Related]
31. ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling.
Meng E; Mitra A; Tripathi K; Finan MA; Scalici J; McClellan S; Madeira da Silva L; Reed E; Shevde LA; Palle K; Rocconi RP
PLoS One; 2014; 9(9):e107142. PubMed ID: 25216266
[TBL] [Abstract][Full Text] [Related]
32. Establishment and Characterization of an In Vitro Model of Ovarian Cancer Stem-like Cells with an Enhanced Proliferative Capacity.
Ishiguro T; Sato A; Ohata H; Ikarashi Y; Takahashi RU; Ochiya T; Yoshida M; Tsuda H; Onda T; Kato T; Kasamatsu T; Enomoto T; Tanaka K; Nakagama H; Okamoto K
Cancer Res; 2016 Jan; 76(1):150-60. PubMed ID: 26669863
[TBL] [Abstract][Full Text] [Related]
33. Increased production of retinoic acid by intestinal macrophages contributes to their inflammatory phenotype in patients with Crohn's disease.
Sanders TJ; McCarthy NE; Giles EM; Davidson KL; Haltalli ML; Hazell S; Lindsay JO; Stagg AJ
Gastroenterology; 2014 May; 146(5):1278-88.e1-2. PubMed ID: 24503130
[TBL] [Abstract][Full Text] [Related]
34. Expression of stem cell markers as useful complementary factors in the early detection of urinary bladder carcinogens by immunohistochemistry for γ-H2AX.
Yamada T; Toyoda T; Matsushita K; Cho YM; Akagi JI; Morikawa T; Mizuta Y; Ogawa K
Arch Toxicol; 2021 Feb; 95(2):715-726. PubMed ID: 33211169
[TBL] [Abstract][Full Text] [Related]
35. Functional and molecular characterization of cancer stem-like cells in bladder cancer: a potential signature for muscle-invasive tumors.
Ferreira-Teixeira M; Parada B; Rodrigues-Santos P; Alves V; Ramalho JS; Caramelo F; Sousa V; Reis F; Gomes CM
Oncotarget; 2015 Nov; 6(34):36185-201. PubMed ID: 26452033
[TBL] [Abstract][Full Text] [Related]
36. βIII-tubulin overexpression is linked to aggressive tumor features and genetic instability in urinary bladder cancer.
Hinsch A; Chaker A; Burdelski C; Koop C; Tsourlakis MC; Steurer S; Rink M; Eichenauer TS; Wilczak W; Wittmer C; Fisch M; Simon R; Sauter G; Büschek F; Clauditz T; Minner S; Jacobsen F
Hum Pathol; 2017 Mar; 61():210-220. PubMed ID: 28025079
[TBL] [Abstract][Full Text] [Related]
37. Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy.
Miyata Y; Matsuo T; Nakamura Y; Yasuda T; Ohba K; Takehara K; Sakai H
Anticancer Res; 2018 Mar; 38(3):1629-1635. PubMed ID: 29491095
[TBL] [Abstract][Full Text] [Related]
38. Effect of
Nowacka M; Ginter-Matuszewska B; Świerczewska M; Sterzyńska K; Nowicki M; Januchowski R
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328460
[TBL] [Abstract][Full Text] [Related]
39. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.
Landen CN; Goodman B; Katre AA; Steg AD; Nick AM; Stone RL; Miller LD; Mejia PV; Jennings NB; Gershenson DM; Bast RC; Coleman RL; Lopez-Berestein G; Sood AK
Mol Cancer Ther; 2010 Dec; 9(12):3186-99. PubMed ID: 20889728
[TBL] [Abstract][Full Text] [Related]
40. Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8⁺ T cells.
Visus C; Wang Y; Lozano-Leon A; Ferris RL; Silver S; Szczepanski MJ; Brand RE; Ferrone CR; Whiteside TL; Ferrone S; DeLeo AB; Wang X
Clin Cancer Res; 2011 Oct; 17(19):6174-84. PubMed ID: 21856769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
